|
CCDC109A expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 5.99520433297585E-15 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.38697950294409E-14 |
| Normal-vs-Stage2 |
3.591900E-04 |
| Normal-vs-Stage3 |
5.24949994584745E-09 |
| Normal-vs-Stage4 |
1.10290000021607E-07 |
| Stage1-vs-Stage2 |
9.467600E-02 |
| Stage1-vs-Stage3 |
9.193200E-01 |
| Stage1-vs-Stage4 |
7.948800E-01 |
| Stage2-vs-Stage3 |
1.217820E-01 |
| Stage2-vs-Stage4 |
1.685550E-01 |
| Stage3-vs-Stage4 |
8.899400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.14575016141316E-13 |
| Normal-vs-AfricanAmerican |
3.423600E-03 |
| Normal-vs-Asian |
2.44200000221184E-08 |
| Caucasian-vs-AfricanAmerican |
6.533800E-01 |
| Caucasian-vs-Asian |
6.312400E-01 |
| AfricanAmerican-vs-Asian |
4.558200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
6.11859451993269E-11 |
| Normal-vs-Female |
1.76059167245057E-12 |
| Male-vs-Female |
2.282000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
6.66133814775094E-15 |
| Normal-vs-Age(41-60Yrs) |
2.64930000160035E-08 |
| Normal-vs-Age(61-80Yrs) |
1.24370003184993E-09 |
| Normal-vs-Age(81-100Yrs) |
1.625240E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.076420E-03 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.404650E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.482600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.308200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.273200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.467400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.220000E-01 |
| Classical-VS-Follicular |
1.384200E-02 |
| Classical-VS-Other |
9.255400E-01 |
| Classical-VS-Normal |
1.62525548574877E-12 |
| Tall-VS-Follicular |
3.171900E-02 |
| Tall-VS-Other |
5.969800E-01 |
| Tall-VS-Normal |
1.53131999999223E-05 |
| Follicular-VS-Other |
4.965400E-01 |
| Follicular-VS-Normal |
8.14749999999975E-05 |
| Other-VS-Normal |
3.162000E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.51170001358747E-09 |
| Normal-vs-N1 |
5.34330000023786E-07 |
| N0-vs-N1 |
6.324000E-02 |
|
|
